25 XP   0   0   10

Genscript Biotech Corp
Buy, Hold or Sell?

Let's analyse Genscript together

PenkeI guess you are interested in Genscript Biotech Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genscript Biotech Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Genscript Biotech Corp

I send you an email if I find something interesting about Genscript Biotech Corp.

Quick analysis of Genscript (30 sec.)










What can you expect buying and holding a share of Genscript? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
HK$3.73
Expected worth in 1 year
HK$5.65
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
HK$1.93
Return On Investment
16.8%

For what price can you sell your share?

Current Price per Share
HK$11.50
Expected price per share
HK$0 - HK$17.06
How sure are you?
50%

1. Valuation of Genscript (5 min.)




Live pricePrice per Share (EOD)

HK$11.50

Intrinsic Value Per Share

HK$-14.07 - HK$-13.09

Total Value Per Share

HK$-10.35 - HK$-9.36

2. Growth of Genscript (5 min.)




Is Genscript growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$879.7m$130.7m12.9%

How much money is Genscript making?

Current yearPrevious yearGrowGrow %
Making money-$28.9m-$44.4m$15.4m53.3%
Net Profit Margin-36.3%-68.1%--

How much money comes from the company's main activities?

3. Financial Health of Genscript (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#57 / 1019

Most Revenue
#115 / 1019

Most Profit
#783 / 1019

Most Efficient
#522 / 1019

What can you expect buying and holding a share of Genscript? (5 min.)

Welcome investor! Genscript's management wants to use your money to grow the business. In return you get a share of Genscript.

What can you expect buying and holding a share of Genscript?

First you should know what it really means to hold a share of Genscript. And how you can make/lose money.

Speculation

The Price per Share of Genscript is HK$11.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genscript.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genscript, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$3.73. Based on the TTM, the Book Value Change Per Share is HK$0.48 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genscript.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps-0.01-0.1%-0.01-0.1%-0.02-0.2%-0.01-0.1%0.000.0%
Usd Book Value Change Per Share0.060.5%0.060.5%0.030.3%0.070.6%0.050.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.060.5%0.060.5%0.030.3%0.070.6%0.050.4%
Usd Price Per Share3.17-3.17-4.41-2.52-1.58-
Price to Earnings Ratio-232.67--232.67--210.65-21.01-217.76-
Price-to-Total Gains Ratio51.54-51.54-145.85-35.12-40.12-
Price to Book Ratio6.67-6.67-10.64-7.93-7.10-
Price-to-Total Gains Ratio51.54-51.54-145.85-35.12-40.12-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.46855
Number of shares680
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.060.07
Usd Total Gains Per Share0.060.07
Gains per Quarter (680 shares)41.8750.08
Gains per Year (680 shares)167.48200.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101671570200190
203353240401390
305024910601590
406706580801790
5083782501002990
601005992012021190
7011721159014021390
8013401326016031590
9015071493018031790
10016751660020031990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%5.04.01.050.0%5.04.02.045.5%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%10.01.00.090.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%4.00.06.040.0%4.00.07.036.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%10.01.00.090.9%

Fundamentals of Genscript

About Genscript Biotech Corp

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company also offers neoantigen peptides and peptide active pharmaceutical ingredients. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-15 23:30:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Genscript Biotech Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genscript earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • A Net Profit Margin of -36.3% means that $-0.36 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genscript Biotech Corp:

  • The MRQ is -36.3%. The company is making a huge loss. -2
  • The TTM is -36.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-36.3%TTM-36.3%0.0%
TTM-36.3%YOY-68.1%+31.8%
TTM-36.3%5Y-36.6%+0.4%
5Y-36.6%10Y-11.4%-25.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.3%-197.2%+160.9%
TTM-36.3%-210.4%+174.1%
YOY-68.1%-279.3%+211.2%
5Y-36.6%-436.8%+400.2%
10Y-11.4%-599.3%+587.9%
1.1.2. Return on Assets

Shows how efficient Genscript is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • -1.1% Return on Assets means that Genscript generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genscript Biotech Corp:

  • The MRQ is -1.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.1%TTM-1.1%0.0%
TTM-1.1%YOY-2.0%+0.9%
TTM-1.1%5Y-1.2%+0.1%
5Y-1.2%10Y-0.2%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.1%-13.6%+12.5%
TTM-1.1%-12.9%+11.8%
YOY-2.0%-11.9%+9.9%
5Y-1.2%-14.2%+13.0%
10Y-0.2%-16.2%+16.0%
1.1.3. Return on Equity

Shows how efficient Genscript is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • -2.9% Return on Equity means Genscript generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genscript Biotech Corp:

  • The MRQ is -2.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.9%TTM-2.9%0.0%
TTM-2.9%YOY-5.0%+2.2%
TTM-2.9%5Y-2.7%-0.2%
5Y-2.7%10Y-0.7%-2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-17.0%+14.1%
TTM-2.9%-16.1%+13.2%
YOY-5.0%-15.4%+10.4%
5Y-2.7%-20.0%+17.3%
10Y-0.7%-21.1%+20.4%

1.2. Operating Efficiency of Genscript Biotech Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genscript is operating .

  • Measures how much profit Genscript makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genscript Biotech Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-96.7%+96.7%
TTM-5Y-42.0%+42.0%
5Y-42.0%10Y-13.3%-28.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY-96.7%-288.4%+191.7%
5Y-42.0%-475.2%+433.2%
10Y-13.3%-624.7%+611.4%
1.2.2. Operating Ratio

Measures how efficient Genscript is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.20 means that the operating costs are $2.20 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genscript Biotech Corp:

  • The MRQ is 2.198. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.198. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.198TTM2.1980.000
TTM2.198YOY2.088+0.110
TTM2.1985Y1.708+0.490
5Y1.70810Y1.206+0.502
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1982.997-0.799
TTM2.1983.247-1.049
YOY2.0883.766-1.678
5Y1.7085.675-3.967
10Y1.2067.857-6.651

1.3. Liquidity of Genscript Biotech Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genscript is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.23 means the company has $3.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genscript Biotech Corp:

  • The MRQ is 3.233. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.233. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.233TTM3.2330.000
TTM3.233YOY3.527-0.295
TTM3.2335Y3.337-0.104
5Y3.33710Y2.813+0.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2333.930-0.697
TTM3.2334.251-1.018
YOY3.5275.436-1.909
5Y3.3376.045-2.708
10Y2.8136.363-3.550
1.3.2. Quick Ratio

Measures if Genscript is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • A Quick Ratio of 3.68 means the company can pay off $3.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genscript Biotech Corp:

  • The MRQ is 3.676. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.676. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.676TTM3.6760.000
TTM3.676YOY3.791-0.116
TTM3.6765Y3.699-0.024
5Y3.69910Y2.913+0.786
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6763.629+0.047
TTM3.6764.065-0.389
YOY3.7915.397-1.606
5Y3.6995.993-2.294
10Y2.9136.277-3.364

1.4. Solvency of Genscript Biotech Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genscript assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genscript to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.60 means that Genscript assets are financed with 60.3% credit (debt) and the remaining percentage (100% - 60.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genscript Biotech Corp:

  • The MRQ is 0.603. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.603. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.603TTM0.6030.000
TTM0.603YOY0.606-0.003
TTM0.6035Y0.538+0.065
5Y0.53810Y0.431+0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6030.332+0.271
TTM0.6030.334+0.269
YOY0.6060.268+0.338
5Y0.5380.366+0.172
10Y0.4310.390+0.041
1.4.2. Debt to Equity Ratio

Measures if Genscript is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genscript to the Biotechnology industry mean.
  • A Debt to Equity ratio of 152.0% means that company has $1.52 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genscript Biotech Corp:

  • The MRQ is 1.520. The company is just able to pay all its debts with equity.
  • The TTM is 1.520. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.520TTM1.5200.000
TTM1.520YOY1.538-0.018
TTM1.5205Y1.199+0.321
5Y1.19910Y0.881+0.318
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5200.381+1.139
TTM1.5200.390+1.130
YOY1.5380.334+1.204
5Y1.1990.434+0.765
10Y0.8810.466+0.415

2. Market Valuation of Genscript Biotech Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genscript generates.

  • Above 15 is considered overpriced but always compare Genscript to the Biotechnology industry mean.
  • A PE ratio of -232.67 means the investor is paying $-232.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genscript Biotech Corp:

  • The EOD is -107.676. Based on the earnings, the company is expensive. -2
  • The MRQ is -232.673. Based on the earnings, the company is expensive. -2
  • The TTM is -232.673. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-107.676MRQ-232.673+124.997
MRQ-232.673TTM-232.6730.000
TTM-232.673YOY-210.654-22.020
TTM-232.6735Y21.008-253.681
5Y21.00810Y217.759-196.751
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-107.676-2.315-105.361
MRQ-232.673-2.560-230.113
TTM-232.673-2.664-230.009
YOY-210.654-4.122-206.532
5Y21.008-6.258+27.266
10Y217.759-6.108+223.867
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genscript Biotech Corp:

  • The EOD is -9.632. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -20.812. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -20.812. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.632MRQ-20.812+11.181
MRQ-20.812TTM-20.8120.000
TTM-20.812YOY-68.411+47.598
TTM-20.8125Y-25.684+4.871
5Y-25.68410Y-56.624+30.941
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.632-3.067-6.565
MRQ-20.812-3.251-17.561
TTM-20.812-3.545-17.267
YOY-68.411-5.595-62.816
5Y-25.684-8.315-17.369
10Y-56.624-8.708-47.916
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genscript is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.67 means the investor is paying $6.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genscript Biotech Corp:

  • The EOD is 3.087. Based on the equity, the company is fair priced.
  • The MRQ is 6.670. Based on the equity, the company is overpriced. -1
  • The TTM is 6.670. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.087MRQ6.670-3.583
MRQ6.670TTM6.6700.000
TTM6.670YOY10.637-3.967
TTM6.6705Y7.930-1.260
5Y7.93010Y7.105+0.825
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.0871.905+1.182
MRQ6.6702.111+4.559
TTM6.6702.095+4.575
YOY10.6372.836+7.801
5Y7.9303.443+4.487
10Y7.1053.794+3.311
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genscript Biotech Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4820.4820%0.237+104%0.577-16%0.356+35%
Book Value Per Share--3.7263.7260%3.243+15%2.633+41%1.566+138%
Current Ratio--3.2333.2330%3.527-8%3.337-3%2.813+15%
Debt To Asset Ratio--0.6030.6030%0.6060%0.538+12%0.431+40%
Debt To Equity Ratio--1.5201.5200%1.538-1%1.199+27%0.881+73%
Dividend Per Share----0%-0%-0%0.004-100%
Eps---0.107-0.1070%-0.164+53%-0.081-25%-0.037-66%
Free Cash Flow Per Share---1.194-1.1940%-0.504-58%-0.401-66%-0.210-82%
Free Cash Flow To Equity Per Share--0.3520.3520%2.822-88%1.221-71%0.722-51%
Gross Profit Margin--1.0001.0000%1.0000%0.884+13%0.315+218%
Intrinsic Value_10Y_max---13.088--------
Intrinsic Value_10Y_min---14.071--------
Intrinsic Value_1Y_max---0.599--------
Intrinsic Value_1Y_min---0.927--------
Intrinsic Value_3Y_max---2.343--------
Intrinsic Value_3Y_min---3.220--------
Intrinsic Value_5Y_max---4.741--------
Intrinsic Value_5Y_min---5.972--------
Market Cap24426344448.000-116%52782144307.20052782144307.2000%73279033344.000-28%41937229697.679+26%26246914240.758+101%
Net Profit Margin---0.363-0.3630%-0.681+88%-0.366+1%-0.114-69%
Operating Margin----0%-0.9670%-0.4200%-0.1330%
Operating Ratio--2.1982.1980%2.088+5%1.708+29%1.206+82%
Pb Ratio3.087-116%6.6706.6700%10.637-37%7.930-16%7.105-6%
Pe Ratio-107.676+54%-232.673-232.6730%-210.654-9%21.008-1208%217.759-207%
Price Per Share11.500-116%24.85024.8500%34.500-28%19.744+26%12.357+101%
Price To Free Cash Flow Ratio-9.632+54%-20.812-20.8120%-68.411+229%-25.684+23%-56.624+172%
Price To Total Gains Ratio23.850-116%51.53651.5360%145.853-65%35.119+47%40.124+28%
Quick Ratio--3.6763.6760%3.791-3%3.699-1%2.913+26%
Return On Assets---0.011-0.0110%-0.020+75%-0.012+6%-0.002-84%
Return On Equity---0.029-0.0290%-0.050+76%-0.027-6%-0.007-75%
Total Gains Per Share--0.4820.4820%0.237+104%0.577-16%0.360+34%
Usd Book Value--1010521183.2911010521183.2910%879733748.083+15%714281992.655+41%424729470.892+138%
Usd Book Value Change Per Share--0.0620.0620%0.030+104%0.074-16%0.045+35%
Usd Book Value Per Share--0.4760.4760%0.414+15%0.336+41%0.200+138%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.014-0.0140%-0.021+53%-0.010-25%-0.005-66%
Usd Free Cash Flow---323857649.027-323857649.0270%-136787317.548-58%-108884864.726-66%-51384692.326-84%
Usd Free Cash Flow Per Share---0.152-0.1520%-0.064-58%-0.051-66%-0.027-82%
Usd Free Cash Flow To Equity Per Share--0.0450.0450%0.360-88%0.156-71%0.092-51%
Usd Market Cap3119244186.010-116%6740279828.0296740279828.0290%9357732558.029-28%5355384232.394+26%3351730948.545+101%
Usd Price Per Share1.469-116%3.1733.1730%4.406-28%2.521+26%1.578+101%
Usd Profit---28968872.700-28968872.7000%-44422360.500+53%-21845817.780-25%-9952746.450-66%
Usd Revenue--79901634.60079901634.6000%65262617.400+22%51883590.560+54%32124914.350+149%
Usd Total Gains Per Share--0.0620.0620%0.030+104%0.074-16%0.046+34%
 EOD+2 -6MRQTTM+0 -0YOY+19 -135Y+13 -2010Y+17 -18

3.2. Fundamental Score

Let's check the fundamental score of Genscript Biotech Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-107.676
Price to Book Ratio (EOD)Between0-13.087
Net Profit Margin (MRQ)Greater than0-0.363
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.676
Current Ratio (MRQ)Greater than13.233
Debt to Asset Ratio (MRQ)Less than10.603
Debt to Equity Ratio (MRQ)Less than11.520
Return on Equity (MRQ)Greater than0.15-0.029
Return on Assets (MRQ)Greater than0.05-0.011
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Genscript Biotech Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.683
Ma 20Greater thanMa 5013.929
Ma 50Greater thanMa 10014.416
Ma 100Greater thanMa 20016.776
OpenGreater thanClose11.640
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets2,546,383
Total Liabilities1,535,842
Total Stockholder Equity1,010,541
 As reported
Total Liabilities 1,535,842
Total Stockholder Equity+ 1,010,541
Total Assets = 2,546,383

Assets

Total Assets2,546,383
Total Current Assets1,764,950
Long-term Assets781,433
Total Current Assets
Cash And Cash Equivalents 1,023,999
Short-term Investments 439,330
Net Receivables 104,089
Inventory 59,935
Other Current Assets 44,076
Total Current Assets  (as reported)1,764,950
Total Current Assets  (calculated)1,671,429
+/- 93,521
Long-term Assets
Property Plant Equipment 646,923
Goodwill 2,547
Intangible Assets 23,811
Other Assets 85,290
Long-term Assets  (as reported)781,433
Long-term Assets  (calculated)758,571
+/- 22,862

Liabilities & Shareholders' Equity

Total Current Liabilities545,978
Long-term Liabilities637,737
Total Stockholder Equity1,010,541
Total Current Liabilities
Short-term Debt 33,230
Short Long Term Debt 33,681
Accounts payable 55,755
Total Current Liabilities  (as reported)545,978
Total Current Liabilities  (calculated)122,666
+/- 423,312
Long-term Liabilities
Long term Debt Total 305,014
Long term Debt 261,006
Capital Lease Obligations 55,112
Long-term Liabilities Other 313
Long-term Liabilities  (as reported)637,737
Long-term Liabilities  (calculated)621,445
+/- 16,292
Total Stockholder Equity
Common Stock2,111
Retained Earnings -427,759
Capital Surplus 1,473,027
Other Stockholders Equity -24,916
Total Stockholder Equity (as reported)1,010,541
Total Stockholder Equity (calculated)1,022,463
+/- 11,922
Other
Capital Stock2,111
Cash And Equivalents1,023,999
Cash and Short Term Investments 1,463,329
Common Stock Shares Outstanding 2,111,226
Liabilities and Stockholders Equity 2,546,383
Net Invested Capital 1,305,228
Net Working Capital 1,218,972
Property Plant and Equipment Gross 790,134



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
75,589
83,835
92,380
182,074
226,032
504,264
916,976
889,411
1,447,406
2,232,770
2,546,383
2,546,3832,232,7701,447,406889,411916,976504,264226,032182,07492,38083,83575,589
   > Total Current Assets 
0
0
43,792
133,014
163,909
397,895
679,463
554,046
993,174
1,637,962
1,764,950
1,764,9501,637,962993,174554,046679,463397,895163,909133,01443,79200
       Cash And Cash Equivalents 
18,660
22,457
25,637
103,720
136,464
123,857
494,558
252,397
629,058
1,180,971
1,023,999
1,023,9991,180,971629,058252,397494,558123,857136,464103,72025,63722,45718,660
       Short-term Investments 
567
4,306
2,526
202
202
3,088
70,056
174,127
142,111
222,233
439,330
439,330222,233142,111174,12770,0563,0882022022,5264,306567
       Net Receivables 
8,574
9,379
12,692
25,975
21,005
259,603
82,582
87,649
165,707
135,176
104,089
104,089135,176165,70787,64982,582259,60321,00525,97512,6929,3798,574
       Other Current Assets 
1,054
1,015
815
1,087
1,832
4,147
18,790
18,171
20,877
16,936
44,076
44,07616,93620,87718,17118,7904,1471,8321,0878151,0151,054
   > Long-term Assets 
0
0
0
0
62,123
106,369
237,513
335,365
454,232
594,808
781,433
781,433594,808454,232335,365237,513106,36962,1230000
       Property Plant Equipment 
38,636
38,271
37,530
37,719
43,735
80,508
158,013
250,292
360,541
492,438
646,923
646,923492,438360,541250,292158,01380,50843,73537,71937,53038,27138,636
       Goodwill 
0
0
0
0
1,384
1,470
15,287
15,245
14,116
14,151
2,547
2,54714,15114,11615,24515,2871,4701,3840000
       Long Term Investments 
0
0
0
0
0
1,750
11,278
7,282
0
0
0
0007,28211,2781,75000000
       Intangible Assets 
211
264
349
901
2,130
2,467
19,642
25,482
50,617
26,423
23,811
23,81126,42350,61725,48219,6422,4672,130901349264211
       Long-term Assets Other 
0
0
0
0
62,123
106,369
237,513
335,365
12,758
6,251
70,245
70,2456,25112,758335,365237,513106,36962,1230000
> Total Liabilities 
31,433
31,272
30,633
32,826
42,011
275,945
423,677
517,113
631,815
1,353,019
1,535,842
1,535,8421,353,019631,815517,113423,677275,94542,01132,82630,63331,27231,433
   > Total Current Liabilities 
30,252
29,885
29,188
30,894
39,215
272,716
153,515
224,505
327,911
464,367
545,978
545,978464,367327,911224,505153,515272,71639,21530,89429,18829,88530,252
       Short-term Debt 
0
0
8,172
0
0
0
10,502
17,008
44,642
0
33,230
33,230044,64217,00810,5020008,17200
       Short Long Term Debt 
0
0
8,172
0
0
0
10,502
17,008
44,642
521
33,681
33,68152144,64217,00810,5020008,17200
       Accounts payable 
1,895
1,848
2,870
2,414
4,352
8,154
11,187
17,627
23,376
30,176
55,755
55,75530,17623,37617,62711,1878,1544,3522,4142,8701,8481,895
       Other Current Liabilities 
23,414
20,647
26,318
17,588
18,404
250,233
94,807
98,953
142,905
264,537
0
0264,537142,90598,95394,807250,23318,40417,58826,31820,64723,414
   > Long-term Liabilities 
0
0
0
0
2,796
3,229
270,162
292,608
303,904
675,448
637,737
637,737675,448303,904292,608270,1623,2292,7960000
       Long term Debt Total 
0
0
0
0
0
0
0
5,356
7,773
148,419
305,014
305,014148,4197,7735,3560000000
       Capital Lease Obligations Min Short Term Debt
0
0
-8,172
0
0
0
-10,502
-11,631
-35,541
34,859
21,882
21,88234,859-35,541-11,631-10,502000-8,17200
       Long-term Liabilities Other 
0
0
0
0
2,349
2,887
4,018
3,843
554
396
313
3133965543,8434,0182,8872,3490000
> Total Stockholder Equity
44,156
52,530
61,714
149,248
177,613
217,809
478,664
382,804
901,705
879,751
1,010,541
1,010,541879,751901,705382,804478,664217,809177,613149,24861,71452,53044,156
   Common Stock
364
364
364
1,600
1,692
1,734
1,836
1,879
1,954
2,096
2,111
2,1112,0961,9541,8791,8361,7341,6921,600364364364
   Retained Earnings 
25,427
31,427
33,604
48,689
72,029
93,228
112,554
15,580
-189,365
-522,871
-427,759
-427,759-522,871-189,36515,580112,55493,22872,02948,68933,60431,42725,427
   Capital Surplus 
0
0
0
106,655
118,051
120,770
364,100
368,781
1,066,547
1,352,180
1,473,027
1,473,0271,352,1801,066,547368,781364,100120,770118,051106,655000
   Treasury Stock0-15,753-16,712-7,7740000000
   Other Stockholders Equity 
0
0
24,062
-14,113
-23,406
-9,459
-14,185
-10,021
24,922
64,099
-24,916
-24,91664,09924,922-10,021-14,185-9,459-23,406-14,11324,06200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in HKD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue625,698
Cost of Revenue-321,615
Gross Profit304,083304,083
 
Operating Income (+$)
Gross Profit304,083
Operating Expense-1,053,454
Operating Income-418,394-749,371
 
Operating Expense (+$)
Research Development390,096
Selling General Administrative351,963
Selling And Marketing Expenses-
Operating Expense1,053,454742,059
 
Net Interest Income (+$)
Interest Income12,193
Interest Expense-13,218
Other Finance Cost-974
Net Interest Income-51
 
Pretax Income (+$)
Operating Income-418,394
Net Interest Income-51
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-431,690-418,394
EBIT - interestExpense = -13,218
-226,851
-213,633
Interest Expense13,218
Earnings Before Interest and Taxes (EBIT)--418,472
Earnings Before Interest and Taxes (EBITDA)-354,173
 
After tax Income (+$)
Income Before Tax-431,690
Tax Provision--3,719
Net Income From Continuing Ops-427,971-427,971
Net Income-226,851
Net Income Applicable To Common Shares-226,851
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-51
 

Technical Analysis of Genscript
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genscript. The general trend of Genscript is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genscript's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genscript Biotech Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 12.56 < 13.80 < 17.06.

The bearish price targets are: .

Tweet this
Genscript Biotech Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genscript Biotech Corp. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genscript Biotech Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genscript Biotech Corp. The current macd is -0.90929652.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Genscript price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genscript. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genscript price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Genscript Biotech Corp Daily Moving Average Convergence/Divergence (MACD) ChartGenscript Biotech Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genscript Biotech Corp. The current adx is 27.48.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Genscript shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Genscript Biotech Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genscript Biotech Corp. The current sar is 13.99.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Genscript Biotech Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genscript Biotech Corp. The current rsi is 29.68. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Genscript Biotech Corp Daily Relative Strength Index (RSI) ChartGenscript Biotech Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genscript Biotech Corp. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Genscript price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Genscript Biotech Corp Daily Stochastic Oscillator ChartGenscript Biotech Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genscript Biotech Corp. The current cci is -135.9657495.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Genscript Biotech Corp Daily Commodity Channel Index (CCI) ChartGenscript Biotech Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genscript Biotech Corp. The current cmo is -53.93060661.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Genscript Biotech Corp Daily Chande Momentum Oscillator (CMO) ChartGenscript Biotech Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genscript Biotech Corp. The current willr is -95.13513514.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Genscript Biotech Corp Daily Williams %R ChartGenscript Biotech Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genscript Biotech Corp.

Genscript Biotech Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genscript Biotech Corp. The current atr is 0.8053663.

Genscript Biotech Corp Daily Average True Range (ATR) ChartGenscript Biotech Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genscript Biotech Corp. The current obv is -211,751,101.

Genscript Biotech Corp Daily On-Balance Volume (OBV) ChartGenscript Biotech Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genscript Biotech Corp. The current mfi is 27.87.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Genscript Biotech Corp Daily Money Flow Index (MFI) ChartGenscript Biotech Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genscript Biotech Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Genscript Biotech Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genscript Biotech Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.683
Ma 20Greater thanMa 5013.929
Ma 50Greater thanMa 10014.416
Ma 100Greater thanMa 20016.776
OpenGreater thanClose11.640
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genscript with someone you think should read this too:
  • Are you bullish or bearish on Genscript? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genscript? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genscript Biotech Corp

I send you an email if I find something interesting about Genscript Biotech Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Genscript Biotech Corp.

Receive notifications about Genscript Biotech Corp in your mailbox!